Catastrophe Risk and Reinsurance - The company has incurred significant losses from catastrophe events multiple times in its history, with the unpredictability of such events posing a risk to earnings and stockholders' equity [127]. - The company's reinsurance coverage currently exhausts at $3.1 billion for earthquake events and $100 million for continental U.S. hurricane events, with a retention of $20 million for earthquake events and $11 million for hurricane events [131]. - As of December 31, 2025, the company had $468.7 million of aggregate reinsurance recoverables, indicating reliance on reinsurance for risk management [133]. - The company closed a $525 million catastrophe bond in Q2 2025, effective June 1, 2025 through June 1, 2028, to enhance its reinsurance coverage for earthquake events [143]. - The company may face increased costs or limitations in purchasing reinsurance during hard market cycles, which could adversely impact its business and results of operations [142]. - The company is exposed to risks from unpredictable catastrophe events, including those caused by climate change, which could limit its ability to underwrite new insurance policies [124]. Competition and Market Position - The company faces intense competition in the insurance industry, which may result in pricing pressure and reduced underwriting margins [124]. - The company faces intense competition from larger specialty insurance companies and public enterprises, which may result in pricing pressure and reduced underwriting margins [170]. - Increased competition in the insurance industry may arise from new entrants and federal regulatory reforms, potentially affecting pricing and business retention [172]. Financial Performance and Risk Management - The reserve for losses and loss adjustment expenses is based on estimates and assumptions, which may prove inadequate, potentially impacting net income and stockholders' equity [134]. - The company relies on third-party data for risk modeling, which may lead to materially higher actual losses if estimates are incorrect [149]. - The company’s risk management approach relies on subjective variables and models that may not accurately predict actual outcomes, introducing uncertainty into loss estimates [151]. - The concentration of business in California exposes the company to greater regulatory and economic risks compared to insurers with a more diversified premium base [160]. - The company’s written premium in future years could be materially adversely affected if actual renewals of existing policies do not meet expectations [174]. Growth and Expansion - The company’s employee base has approximately doubled in the last twelve months, indicating significant growth and potential challenges in managing this expansion [181]. - Recent acquisitions include Gray Surety in January 2026 and FIA and AAP in 2025, which are part of the company’s strategy to expand its business [182]. - The company faces risks related to the evaluation and integration of acquired businesses, which could impact financial performance and operational efficiency [183]. Economic and Regulatory Environment - Economic downturns, particularly in California, could adversely affect the company’s financial condition and results of operations [196]. - The company is subject to extensive regulations that may adversely affect its ability to achieve business objectives and could result in penalties for non-compliance [224]. - U.S. insurance subsidiaries must maintain risk-based capital at required levels to avoid regulatory actions, including supervision or liquidation [228]. - The Bermuda subsidiary is subject to the Economic Substance Act 2018, which may require changes to business operations to comply with regulations [229]. Investment Risks - The company’s investment portfolio performance is subject to various risks, including interest rate fluctuations and credit quality considerations [199]. - The company faces risks from potential investment losses due to economic downturns, which could lead to impairments in the fixed income portfolio [207]. - The company may need to sell investments to meet liquidity requirements, which could result in significant realized losses depending on market conditions [210]. - The estimated fair value of the company's fixed maturities was $1.2 billion, with a 100-basis point increase in interest rates potentially causing a 3.8% decline in value [454]. - The company's fixed maturity portfolio has an average rating of "AA−," with approximately 71.3% rated "A−" or better, indicating a focus on high credit quality investments [452]. Cybersecurity and Compliance - Increased regulatory scrutiny around cybersecurity incidents could exacerbate potential harm to the company's business and reputation [217]. - The company is required to comply with cybersecurity regulations, which mandate the establishment and maintenance of a cybersecurity program [238]. - Compliance with the Sarbanes-Oxley Act and Dodd-Frank Act has increased regulatory demands and operating costs for the company [255]. - The company incurs significant costs as a public company, including legal and accounting expenses, which divert management's time from revenue-generating activities [253]. Legal and Tax Risks - The company faces risks associated with litigation, which could have an adverse effect on its business and financial condition [247]. - Changes in tax laws could negatively impact the company's results of operations and profitability by increasing tax expenses [241]. - The use of credit scoring in pricing and underwriting is subject to legal and regulatory scrutiny, which could decrease profitability if restrictions are enacted [248]. Dividend Policy - The company does not intend to declare and pay cash dividends in the foreseeable future, relying on its insurance subsidiaries for any potential dividends [244].

Financial Performance - Attruby generated $362.4 million in U.S. net product revenues in 2025, reflecting increasing patient adoption and prescriber utilization [44]. - Beyonttra contributed $105 million in license and services revenue in 2025 following approvals in Europe and Japan [47]. - BridgeBio has obtained FDA approval for three products and has treated over 8,500 patients with its approved medicines [21]. - The company received gross cash proceeds of $500.0 million in December 2024 following FDA approval of Attruby on November 22, 2024 [184]. Market Potential - The total global addressable market for ATTR therapeutic interventions could exceed $20.0 billion, with diagnosed ATTR-CM patients in the U.S. growing from fewer than 5,000 in 2019 to more than 50,000 in 2025 [48]. - The estimated global prevalence of ATTRwt-CM and ATTRv-CM is over 400,000 and 40,000 patients, respectively, indicating significant underdiagnosis in the population [53]. - The market opportunity for achondroplasia and other FGFR-driven skeletal dysplasias is estimated to exceed $5.0 billion globally [82]. - The total global market opportunity for hypochondroplasia is expected to approach that of achondroplasia, driven by growing awareness and clinical trials [120]. Clinical Development - Positive Phase 3 results for infigratinib in achondroplasia, BBP-418 in limb-girdle muscular dystrophy type 2I/R9, and encaleret in autosomal dominant hypocalcemia type 1 are expected to lead to NDA submissions in 2026 [42]. - The Phase 3 PROPEL 3 study for low-dose infigratinib showed a statistically significant improvement in annualized height velocity of +2.10 cm/year compared to placebo [79]. - Enrollment in the Phase 2 portion of the ACCEL 2/3 trial for hypochondroplasia has been completed, with proof-of-concept results expected in the second half of 2026 [122]. - The company plans to initiate a registrational Phase 3 study for encaleret in pediatric ADH1 in Q1 2026 [99]. Regulatory and Compliance - The company is subject to extensive government regulations regarding the research, development, and marketing of drug products, which require significant time and financial resources [186]. - The FDA regulates drugs and biologics under the Federal Food, Drug, and Cosmetic Act, requiring substantial data to demonstrate quality, safety, and efficacy before marketing [188]. - The FDA targets ten months for the initial review of a new molecular entity NDA or original BLA, and six months for priority review applications [203]. - Manufacturers must comply with ongoing FDA regulations post-approval, including monitoring adverse experiences and adhering to advertising standards [219]. Competitive Landscape - Acoramidis (Attruby/Beyonttra) competes with Pfizer's Vyndaqel and Alnylam's vutrisiran for the treatment of ATTR-CM [137]. - The company faces competition from established pharmaceutical and biotechnology companies, which may have greater resources [135][136]. Partnerships and Agreements - Bayer License Agreement granted an exclusive license for acoramidis with an upfront payment of $135.0 million and potential milestone payments up to $600.0 million through 2026 [156]. - Eidos received an upfront payment of $25.0 million from Alexion for the license to commercialize Beyonttra in Japan, with a regulatory milestone payment of $30.0 million recognized in June 2025 [160]. - QED entered into a license agreement with Kyowa Kirin for infigratinib, receiving an upfront payment of $100.0 million and potential milestone payments up to $81.4 million [168]. Product Development and Innovation - The decentralized hub-and-spoke model allows multiple programs to advance concurrently, enhancing the probability of success over time [33]. - BBP-812 has the potential to become the first disease-modifying therapy for Canavan disease, having received multiple designations from the FDA and EMA [124]. - BridgeBio has initiated a next-generation depleter program for ATTR-CM, which could expand the addressable patient population by removing existing amyloid deposits [127].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) No. 41-0449260 (I.R.S. Employer Identification No.) 333 Market Street, San Francisco, California 94105 (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: 415-371-2921 Securities registered pursuant to Section 12(b) of the Act: Annual Report Pursuant ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 1-11314 LTC PROPERTIES, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________. Commission File Number 001-37979 VERRA MOBILITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 81-3563824 (State of I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-12209 RANGE RESOURCES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 34-1312571 (State or Other Jurisdiction of Incorporation or Organization) (IRS ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the "Company", "SLRC", "we", "us", or "our") today reported net investment income ("NII") of $21.6 million, or $0.40 per share, for the fourth quarter of 2025. On February 24, 2026, the Board declared a quarterly distribution of $0.41 per share payable on March 27, 2026, to holders of record as of March 13, 2026. EXHIBIT 99.1 SLR Investment Corp. Announces Quarter and Year Ended December 31, 2025 Financial Results Net Investmen ...

Financial Performance - For the year ended December 31, 2025, consolidated net sales were $4,176.0 million, representing a 2.3% increase from $4,082.8 million in 2024[168]. - Gross profit increased to $1,690.3 million, with a gross margin of 40.5%, up from 39.2% in 2024, primarily due to increased selling prices and improved productivity[168][170]. - Core growth was 1.9% in 2025, driven by increased selling prices, while volume declined by 2.1%[169]. - Cash provided by operating activities of continuing operations was $814.8 million in 2025, up from $766.9 million in 2024[198]. - Free cash flow from continuing operations reached $748.4 million in 2025, compared to $693.1 million in 2024[205]. Segment Performance - The Flow, Water Solutions, and Pool segments accounted for approximately 37%, 25%, and 38% of total consolidated net sales, respectively[161]. - Flow's net sales increased by 2.6% to $1,553.6 million in 2025, while segment income rose by 13.8% to $362.1 million[177]. - Water Solutions experienced a 6.1% decrease in net sales to $1,062.1 million in 2025, with segment income slightly declining by 0.5% to $253.9 million[182]. - Pool segment net sales grew by 8.5% to $1,436.1 million in 2025, with segment income increasing by 10.6% to $527.1 million[188]. - Pool segment's core growth was 6.5% in 2025, driven by increased demand and acquisition contributions[189]. Acquisitions and Investments - The company completed the acquisition of Hydra-Stop for $292.1 million and G & F Manufacturing for $116.0 million, enhancing its product offerings in the Flow and Pool segments[164][165]. - The acquisition of Hydra-Stop for $292.1 million was completed in September 2025, funded by cash on hand and borrowings[197]. - The company plans to continue investing in research and development and market opportunities to drive future growth[167]. Tax and Interest Expenses - The effective tax rate increased to 14.1% in 2025 from 13.0% in 2024, primarily due to a decrease in favorable unrecognized tax benefits[168][172]. - The company experienced a 21.7% decrease in net interest expense, down to $69.4 million in 2025 from $88.6 million in 2024, attributed to lower debt levels[168][172]. Operational Challenges - Inflationary cost increases impacted financial performance, with ongoing pressures from raw materials and logistics costs expected to continue into 2026[166][167]. - The company implemented a Transformation Program aimed at driving operational excellence and margin expansion, with a focus on pricing and sourcing excellence[166][167]. Backlog and Contractual Obligations - The overall backlog decreased by 7.1% to $567.5 million, primarily due to timing of delivery associated with advance sale programs in the Pool segment[193]. - Total contractual obligations, net, amount to $2,190.3 million, with $140.9 million due in the next twelve months[221]. Debt and Financial Liabilities - As of December 31, 2025, total availability under the Senior Credit Facility was $622.3 million, with an option to increase the revolving credit facility by up to $450.0 million[207]. - The Term Loan Facility has an aggregate principal amount of $1.0 billion, with remaining obligations of $575.0 million maturing on July 28, 2027[208][209]. - As of December 31, 2025, variable interest rate debt was $852.7 million at a weighted average interest rate of 5.03%[222]. - The total gross liability for uncertain tax positions was estimated to be $6.7 million as of December 31, 2025[223]. - The outstanding value of bonds, letters of credit, and bank guarantees totaled $115.0 million as of December 31, 2025[229]. Shareholder Returns - The company repurchased 2.3 million ordinary shares for $225.0 million during the year ended December 31, 2025, under the 2020 Authorization[214]. - The Board of Directors approved a quarterly cash dividend of $0.27 per share, reflecting an 8% increase, with total dividends paid per ordinary share of $1.00 for the year ended December 31, 2025[215]. - Distributable reserves were $6.4 billion as of December 31, 2025, down from $6.8 billion in 2024[216]. Financial Instruments and Risks - As of December 31, 2025, the debt portfolio comprised 48% fixed-rate debt and 52% variable-rate debt[250]. - A 100 basis point increase or decrease in interest rates would result in approximately a $38 million decrease or a $40 million increase in the fair value of total fixed-rate debt outstanding[251]. - As of December 31, 2025, the company had outstanding foreign currency derivative contracts with gross notional U.S. dollar equivalent amounts of $23.2 million[255]. - The company had outstanding cross currency swap agreements with a combined notional amount of $1.1 billion as of December 31, 2025[256]. - A 10% appreciation or depreciation of the U.S. dollar relative to the Euro would result in a change in accumulated other comprehensive income of approximately $80 million[256]. Pension and Retirement Plans - The company sponsors U.S. and non-U.S. defined-benefit pension and other post-retirement plans, with actuarial valuations determining the amounts recognized in financial statements[239]. - A 100 basis point increase or decrease in the discount rates would result in an approximate decrease of $5 million or increase of $6 million in the total projected benefit obligation[243]. Impairment and Adjustments - An impairment charge of $30.9 million was recorded in 2025 related to the write-off of a definite-lived customer relationship intangible asset[236]. - Mark-to-market adjustments resulted in pre-tax losses of $2.4 million and $6.1 million in 2025 and 2023, respectively, and a pre-tax gain of $5.3 million in 2024[240]. - No impairment charges associated with identifiable intangibles with finite lives were recognized in 2024 or 2023[236].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K _________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission File Number: 1-10853 TRUIST FINANCIAL CORPORATION (Exact name of registrant as specified in its charter) _________________________________________________________________ North Carolina 56-0939887 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Commission file number 0-27078 HENRY SCHEIN, INC. (Exact name of registrant as specified in its charter) Delaware 11-3136595 incorporation or organization) (State or other jurisdiction of (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.01 per share HSIC The Nasdaq ...